LEO Pharma and ICON Enter Strategic Partnership
Partnership will enable LEO Pharma to scale patient-centric and cost effective clinical trial execution.
LEO Pharma and ICON have announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective. The mission of the partnership is to improve the lives of dermatology patients with access to innovative clinical trials and the launch of new medicines.
The partnership will leverage both fully outsourced and functional outsourcing models in a hybrid approach. In supporting LEO Pharma through this partnership, ICON will draw upon a team from across its business to deliver tailored solutions, bringing capabilities including its laboratories, Accellacare site-network, FIRECREST site management, and DCT capabilities.
Reference
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology. (2023, March 10). Business Wire.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025